Solara Active Pharma Sciences CEO, MD, chairman, board of directors and AGM
NSE: SOLARABSE: 541540Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹619.05.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹2,951 Cr1,182nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 16 Oct 2026
- 79.9
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹10 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 62.3
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 16 Oct 2026
- 2.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 16 Oct 2026
- 2.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹10 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 3.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 16 Oct 2026
- 6.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. The filing of 16 Oct 2026
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 5,34,15343.0% delivered
Solara Active Pharma Sciences board of directors
At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- ChairpersonRamakrishnan Rajagopal
- Managing director and CEOSandeep Shashikantha Rao
- Company Secretary and Compliance OfficerPooja Jaya Kumar
8 directors4 independent2 executive2 non-executive
- Ramakrishnan Rajagopal · ChairpersonIndependent · joined Apr 2018 · reappointed Apr 2023 · 98 months as independent · 1 listed board · 1 as independent
- Kausalya SanthanamIndependent · joined Apr 2018 · reappointed Apr 2023 · 98 months as independent · 2 listed boards · 2 as independent · 2 committee seats, 2 as chair
- Arun Kumar PillaiNon-executive · joined Aug 2021 · 3 listed boards · 1 committee seat
- Sandeep Shashikantha Rao · Managing director and CEOExecutive · joined Feb 2025 · 1 listed board · 1 committee seat
- Manish GuptaNon-executive · joined Jul 2024 · 2 listed boards · 2 committee seats
- Rajendra Kumar SrivastavaIndependent · joined Nov 2023 · reappointed Nov 2023 · 31 months as independent · 2 listed boards · 2 as independent · 2 committee seats
- Rajiv Vijay NabarIndependent · joined Nov 2023 · reappointed Nov 2023 · 31 months as independent · 2 listed boards · 2 as independent · 3 committee seats
- Mohanraj SanjeeviExecutive · joined Jan 2026 · 1 listed board
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
3 directors who left
- Mohan Muthunarayanan, left 31 Dec 2025: Others
- Kartheek Chintalapati Raju, left 5 Nov 2025: Others
- POORVANK PUROHIT, left 21 Feb 2025: Others
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 15 May 20268 of 8 present4 independent · 97 days in between
- 6 Feb 20268 of 8 present4 independent
Audit Committee
Chair Ramakrishnan Rajagopal
Kausalya Santhanam, Rajendra Kumar Srivastava, Rajiv Vijay Nabar
- 15 May 20264 of 4 present4 independent · 51 days in between
- 24 Mar 20264 of 4 present4 independent · 45 days in between
- 6 Feb 20264 of 4 present4 independent
Nomination and remuneration committee
Chair Rajendra Kumar Srivastava
Kausalya Santhanam, Rajiv Vijay Nabar, Ramakrishnan Rajagopal
- 15 May 20264 of 4 present4 independent
Stakeholders Relationship Committee
Chair Kausalya Santhanam
Sandeep Shashikantha Rao, Manish Gupta
No meeting listed in the filing.
Risk Management Committee
Chair Rajiv Vijay Nabar
Kausalya Santhanam, Rajendra Kumar Srivastava, Ramakrishnan Rajagopal, Sandeep Shashikantha Rao
- 15 May 20265 of 5 present4 independent · 97 days in between
- 6 Feb 20265 of 5 present4 independent
Corporate Social Responsibility Committee
Chair Kausalya Santhanam
Ramakrishnan Rajagopal, Sandeep Shashikantha Rao
- 15 May 20263 of 3 present2 independent
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- Delloitte Haskins & Sells LLPPeer-review certificate valid to Jul 2027
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Solara Active Pharma Sciences AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Solara Active Pharma Sciences dividend history
Annual general meeting, 18 Sep 2026
71,549 shareholders on the register on 11 Sep 2026; present: 15 promoters and 44 others; votes counted by Preetham Hebbar / Preetham Hebbar & Co.The company's voting result (opens in a new tab)
- Adoption of Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2026Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 55.61% · promoters 93.28% · institutions 77.15% · other public 11.12%
- Adoption of Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2026Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 55.61% · promoters 93.28% · institutions 77.15% · other public 11.12%
- Appointment of Mr. Arun Kumar Pillai (DIN: 00084845), who retires by rotation, as a Non-Executive Director of the CompanyOrdinaryPromoters have an interest in it99.96% for0.04% against
Against: promoters 0.00% · institutions 0.13% · other public 0.17%
Turnout: all 52.16% · promoters 85.04% · institutions 77.25% · other public 11.12%
- Ratification of the remuneration payable to the Cost Auditor for the financial year 2026-27Ordinary99.97% for0.03% against
Against: promoters 0.00% · institutions 0.00% · other public 0.36%
Turnout: all 55.63% · promoters 93.28% · institutions 77.25% · other public 11.12%
- Approval for Material Related Party Transactions/ Contracts/ Arrangements with Strides Pharma Science Limited up to Rs.480 croresOrdinaryPromoters have an interest in it99.87% for0.13% against
Against: promoters 0.00% · institutions 0.00% · other public 0.46%
Turnout: all 16.23% · promoters 0.00% · institutions 77.25% · other public 10.78%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Postal ballot, 6 Mar 2026, 1 resolution
71,749 shareholders on the register on 30 Jan 2026; votes counted by Preetham Hebbar / Preetham Hebbar & Co..The company's voting result (opens in a new tab)
- Appointment of Mr. Mohanraj Sanjeevi (DIN: 08420411) as a Whole-time Director (Executive Director) of the CompanySpecial99.97% for0.03% against
Against: promoters 0.00% · institutions 0.00% · other public 0.23%
Turnout: all 58.64% · promoters 92.55% · institutions 82.42% · other public 17.82%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Annual general meeting, 25 Sep 2025, 6 resolutions
73,100 shareholders on the register on 18 Sep 2025; present: 16 promoters and 46 others; votes counted by Mr. Preetham Hebbar / Preetham Hebbar & Co..The company's voting result (opens in a new tab)
- Adoption of Audited Financial Statements for the financial year ended March 31, 2025.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 54.89% · promoters 81.60% · institutions 73.19% · other public 24.52%
- Appointment of Mr. Mohan Muthunarayanan, retiring director, as an Executive DirectorOrdinary99.98% for0.02% against
Against: promoters 0.00% · institutions 0.00% · other public 0.08%
Turnout: all 54.90% · promoters 81.60% · institutions 73.27% · other public 24.52%
- Appointment of Mr. Manish Gupta, retiring director, as a Non-Executive DirectorOrdinary99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 0.06%
Turnout: all 54.90% · promoters 81.60% · institutions 73.27% · other public 24.52%
- Ratification of remuneration payable to the Cost Auditor for the financial year 2025-26.Ordinary99.97% for0.04% against
Against: promoters 0.00% · institutions 0.00% · other public 0.18%
Turnout: all 54.90% · promoters 81.60% · institutions 73.27% · other public 24.52%
- Approval for Material Related Party Transactions/ Contracts/ Arrangements with Strides Pharma Science Limited up to Rs. 400 croresOrdinaryPromoters have an interest in it99.87% for0.13% against
Against: promoters 0.00% · institutions 0.00% · other public 0.33%
Turnout: all 21.04% · promoters 0.00% · institutions 73.27% · other public 19.18%
- Approval for appointment of Secretarial Auditor.Ordinary99.99% for0.01% against
Against: promoters 0.00% · institutions 0.02% · other public 0.01%
Turnout: all 54.90% · promoters 81.60% · institutions 73.27% · other public 24.52%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Postal ballot, 19 Apr 2025, 1 resolution
78,312 shareholders on the register on 14 Mar 2025; votes counted by Preetham Hebbar / Preetham Hebbar & Co..The company's voting result (opens in a new tab)
- Appointment of Mr. Sandeep Shashikantha Rao (DIN: 10838251) as Managing Director and Chief Executive Officer (Executive Capacity) of the CompanySpecial99.98% for0.02% against
Against: promoters 0.00% · institutions 0.00% · other public 12.16%
Turnout: all 45.42% · promoters 88.99% · institutions 83.84% · other public 0.19%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Annual general meeting, 20 Sep 2024, 8 resolutions
Present: 10 promoters and 48 others.The company's voting result (opens in a new tab)
- Adoption of Audited Financial Statements(Standalone & Consolidated) for the Financial Year ended March 31, 2024.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 59.07% · promoters 88.78% · institutions 74.24% · other public 32.81%
- Appointment of Mr. Arun Kumar Pillai, retiring director, as a Non-Executive DirectorOrdinary98.74% for1.26% against
Against: promoters 0.00% · institutions 0.00% · other public 4.73%
Turnout: all 59.08% · promoters 88.78% · institutions 74.31% · other public 32.82%
- Appointment of Mr. Kartheek Chintalapati Raju, retiring director, as a Non-Executive DirectorOrdinary93.45% for6.55% against
Against: promoters 0.00% · institutions 21.92% · other public 4.89%
Turnout: all 59.08% · promoters 88.78% · institutions 74.31% · other public 32.82%
- Ratification of remuneration payable to the Cost Auditor for the financial year 2023-24.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 59.08% · promoters 88.78% · institutions 74.31% · other public 32.82%
- Approval for Material Related Party Transactions/ Contracts/ Arrangements with Strides Pharma Science Limited up to ` 400 crores.OrdinaryPromoters have an interest in it99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 0.04%
Turnout: all 59.08% · promoters 88.78% · institutions 74.31% · other public 32.82%
- Appointment of Mr. Manish Gupta (DIN:06805265) as a Non-Executive (Non-Independent) Director of the CompanyOrdinary99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 0.04%
Turnout: all 59.08% · promoters 88.78% · institutions 74.31% · other public 32.82%
- Introduction and Implementation of ‘‘SOLARA EMPLOYEE STOCK OPTION PLAN -2024”Special92.09% for7.91% against
Against: promoters 0.00% · institutions 32.87% · other public 0.18%
Turnout: all 59.08% · promoters 88.78% · institutions 74.31% · other public 32.82%
- Extension of ‘‘SOLARA EMPLOYEE STOCK OPTION PLAN -2024” to Employees of Subsidiary Company(ies) of the CompanySpecial92.09% for7.91% against
Against: promoters 0.00% · institutions 32.87% · other public 0.18%
Turnout: all 59.08% · promoters 88.78% · institutions 74.31% · other public 32.82%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Postal ballot, 6 Apr 2024, 1 resolution
The company's voting result (opens in a new tab)
- Approval for appointment of Mr. Mohan Muthunarayanan (DIN: 03610282) as an Executive Director of the Company.Special92.62% for7.38% against
Against: promoters 0.00% · institutions 29.98% · other public 0.15%
Turnout: all 50.96% · promoters 86.78% · institutions 66.51% · other public 23.69%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Postal ballot, 18 Jan 2024, 2 resolutions
The company's voting result (opens in a new tab)
Approval for Appointment of Mr. Rajendra Kumar Srivastava (DIN: 07500741) as a Non-Executive Independent Director of the Company for a consecutive term of five years commencing from November 14, 2023, to November 13, 2028, and for his continuation after attaining 75 years of age during such tenure.MoreLess
Special100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.01%
Turnout: all 58.91% · promoters 88.09% · institutions 60.86% · other public 37.45%
Approval for Appointment of Mr. Rajiv Vijay Nabar (DIN: 10383397) as a Non-Executive Independent Director of the Company for a consecutive term of five years commencing from November 29, 2023, to November 28, 2028.MoreLess
Special100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.01%
Turnout: all 58.91% · promoters 88.09% · institutions 60.86% · other public 37.45%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Annual general meeting, 15 Sep 2023, 7 resolutions
Present: 16 promoters and 55 others.The company's voting result (opens in a new tab)
- Adoption of Audited Financial Statements for the Financial Year ended March 31, 2023.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 67.35% · promoters 88.71% · institutions 87.09% · other public 39.76%
- Re-Appointment of Mr. Ankur Thadani, retiring director, as a Non-Executive Director.Ordinary88.72% for11.28% against
Against: promoters 0.00% · institutions 43.97% · other public 0.03%
Turnout: all 67.35% · promoters 88.71% · institutions 87.12% · other public 39.76%
- Re-Appointment of Statutory Auditors for the second term of four years.Ordinary99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 0.02%
Turnout: all 67.35% · promoters 88.71% · institutions 87.12% · other public 39.76%
- Ratification of remuneration payable to the Cost Auditor for the financial year 2022-23.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 67.35% · promoters 88.71% · institutions 87.12% · other public 39.76%
- Approval for Material Related Party Transactions/ Contracts/ Arrangements with Strides Pharma Science Limited up to ₹ 300 Crores.OrdinaryPromoters have an interest in it99.98% for0.02% against
Against: promoters 0.00% · institutions 0.00% · other public 0.07%
Turnout: all 22.89% · promoters 0.00% · institutions 87.12% · other public 13.07%
- Appointment of Mr. Kartheek Chintalapati Raju (DIN: 02921819) as a Non-Executive (Non-Independent) Director of the Company.Ordinary97.98% for2.02% against
Against: promoters 0.00% · institutions 7.86% · other public 0.03%
Turnout: all 67.35% · promoters 88.71% · institutions 87.12% · other public 39.76%
- Appointment of Mr. Poorvank Purohit (DIN: 10158900) as a Managing Director & Chief Executive Officer (CEO) of the CompanySpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.01%
Turnout: all 67.35% · promoters 88.71% · institutions 87.12% · other public 39.76%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
How mutual funds voted
Fund houses must disclose how they vote at every meeting of a company they hold.
Mutual fund votes, meeting of 6 Mar 2026, 3 fund houses
- Appointment of Mr. Mohanraj Sanjeevi (DIN: 08420411) as a Whole-time Director (Executive Director) of the Company3 for0 against
Mutual fund votes, meeting of 25 Sep 2025, 3 fund houses
- Adoption of Audited Financial Statements for the financial year ended March 31, 2025.3 for0 against
- Appointment of Mr. Mohan Muthunarayanan, retiring director, as an Executive Director3 for0 against
- Appointment of Mr. Manish Gupta, retiring director, as a Non-Executive Director3 for0 against
- Ratification of remuneration payable to the Cost Auditor for the financial year 2025-26.3 for0 against
- Approval for Material Related Party Transactions/ Contracts/ Arrangements with Strides Pharma Science Limited up to Rs. 400 crores3 for0 against
- Approval for appointment of Secretarial Auditor.
Against Bandhan Mutual Fund, Motilal Oswal Mutual Fund
- Bandhan Mutual Fund, Motilal Oswal Mutual FundCompliant with law. Transparency concern: Previous auditors’ remuneration not disclosed to ascertain any material change in the Audit fee.
1 for2 against
5 earlier meetings
Mutual fund votes, meeting of 19 Apr 2025, 3 fund houses
- Appointment of Mr. Sandeep Shashikantha Rao (DIN: 10838251) as Managing Director and Chief Executive Officer (Executive Capacity) of the Company3 for0 against
Mutual fund votes, meeting of 20 Sep 2024, 3 fund houses
- Adoption of Audited Financial Statements(Standalone & Consolidated) for the Financial Year ended March 31, 2024.3 for0 against
- Appointment of Mr. Arun Kumar Pillai, retiring director, as a Non-Executive Director3 for0 against
- Appointment of Mr. Kartheek Chintalapati Raju, retiring director, as a Non-Executive Director3 for0 against
- Ratification of remuneration payable to the Cost Auditor for the financial year 2023-24.3 for0 against
- Approval for Material Related Party Transactions/ Contracts/ Arrangements with Strides Pharma Science Limited up to ` 400 crores.3 for0 against
- Appointment of Mr. Manish Gupta (DIN:06805265) as a Non-Executive (Non-Independent) Director of the Company3 for0 against
- Introduction and Implementation of ‘‘SOLARA EMPLOYEE STOCK OPTION PLAN -2024”
Against Bandhan Mutual Fund, Motilal Oswal Mutual Fund
- Bandhan Mutual Fund, Motilal Oswal Mutual FundNon-compliant with SEBI (SBEB & SE) Regulations, 2021: Exercise price not disclosed; Vesting period and Exercise period inadequately disclosed. Governance Concern: Excessive benefit may be extended to an individual employee.
1 for2 against - Extension of ‘‘SOLARA EMPLOYEE STOCK OPTION PLAN -2024” to Employees of Subsidiary Company(ies) of the Company
Against Bandhan Mutual Fund, Motilal Oswal Mutual Fund
- Bandhan Mutual Fund, Motilal Oswal Mutual FundNon-compliant with SEBI (SBEB & SE) Regulations, 2021: Exercise price not disclosed; Vesting period and Exercise period inadequately disclosed. Governance Concern: Excessive benefit may be extended to an individual employee.
1 for2 against
Mutual fund votes, meeting of 6 Apr 2024, 2 fund houses
- Approval for appointment of Mr. Mohan Muthunarayanan (DIN: 03610282) as an Executive Director of the Company.2 for0 against
Mutual fund votes, meeting of 18 Jan 2024, 2 fund houses
Approval for Appointment of Mr. Rajendra Kumar Srivastava (DIN: 07500741) as a Non-Executive Independent Director of the Company for a consecutive term of five years commencing from November 14, 2023, to November 13, 2028, and for his continuation after attaining 75 years of age during such tenure.MoreLess
2 for0 againstApproval for Appointment of Mr. Rajiv Vijay Nabar (DIN: 10383397) as a Non-Executive Independent Director of the Company for a consecutive term of five years commencing from November 29, 2023, to November 28, 2028.MoreLess
2 for0 against
Mutual fund votes, meeting of 15 Sep 2023, 2 fund houses
- Adoption of Audited Financial Statements for the Financial Year ended March 31, 2023.2 for0 against
- Re-Appointment of Mr. Ankur Thadani, retiring director, as a Non-Executive Director.2 for0 against
- Re-Appointment of Statutory Auditors for the second term of four years.2 for0 against
- Ratification of remuneration payable to the Cost Auditor for the financial year 2022-23.2 for0 against
- Approval for Material Related Party Transactions/ Contracts/ Arrangements with Strides Pharma Science Limited up to ₹ 300 Crores.2 for0 against
- Appointment of Mr. Kartheek Chintalapati Raju (DIN: 02921819) as a Non-Executive (Non-Independent) Director of the Company.2 for0 against
- Appointment of Mr. Poorvank Purohit (DIN: 10158900) as a Managing Director & Chief Executive Officer (CEO) of the Company2 for0 against
Each fund house counted once, from its own disclosure; the reasons are its own words.
Tax disputes
Reported in the filing for the quarter to Jun 2026.
- Tax disputeDeputy Commissioner of Income tax, Corporate Circle 3(1)Since 6 May 2024Hearing adjourned based on Department representative's requestAt the filing before: Appeal filed before "Income Tax Appellate Tribunal" (ITAT), against the order of "Commissioner of Income Tax (Appeal)" (CIT(A))for Asst. Year 2018-19-Appeal had been numbered, posted for hearing
- Tax disputeDeputy Commissioner of Income tax, Corporate Circle 3(1)Since 6 May 2024Hearing adjourned based on Department representative's requestAt the filing before: Appeal filed before "Income Tax Appellate Tribunal" (ITAT), against the order of "Commissioner of Income Tax (Appeal)" (CIT(A)) for Asst. Year 2020-21-Appeal had been numbered, posted for hearing
- Tax disputeDeputy Commissioner of Income tax, Corporate Circle 3(1)Since 15 Apr 2024Company had made its submissionAt the filing before: Appeal filed before CIT(A), against the assessment order of Assessing Officer (AO), for Asst. year 2022-23-Appeal had been numbered, posted for hearing
- Tax disputeAsst. Commissioner of Income tax, Central Circle 3Since 28 Mar 2025Company had made its submissionAt the filing before: Appeal filed before CIT(A), against the assessment order of Assessing Officer (AO), for Asst. year 2023-24-Appeal had been numbered, posted for hearing
- Tax disputeAsst. Commissioner of Income tax, Central Circle 3Since 26 Mar 2026Status QuoAt the filing before: Appeal filed before CIT(A), against the assessment order of Assessing Officer (AO), for Asst. year 2024-25-Appeal recently filed & yet to numbered
- Tax disputeAsst. Commissioner of Income tax, Central Circle 3Since 9 Apr 2026Appeal had been numbered, Posted for hearing & company had made its submissionAt the filing before: Appeal filed before CIT(A), against the re-opening assessment order of Assessing Officer (AO), for Asst. year 2019-20-Appeal recently filed & yet to numbered
- Tax disputeCommercial Tax Officer, GST (CTO)Since 25 Mar 2026Status QuoAt the filing before: Appeal filed against order of CTO, for levy of tax against ISD credits-Appeal filed & yet to be numbered
In the company's own words, from its latest governance filing.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- Yes
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- Yes
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Sep 2026. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere | Reason and comments |
|---|---|---|---|---|---|---|
| Rights IssuesAug 2026, checked by CRISIL Ratings Limited | 446.62 | Repayment or Pre-payment in full or part of certain outstanding Borrowings availed by the Company. | 334.71 | 334.71 | No | Audit committee: No comments from the Audit Committee |
| Rights IssuesAug 2026, checked by CRISIL Ratings Limited | 446.62 | General Corporate Purpose (GCP) | 112.24 | 105.17 | No | Audit committee: No comments from the Audit Committee |